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Abstract
Background: Rapamycin has gained significant attention for its potential activity in reducing the size of
TSC-associated tumors, thus providing alternative to surgery. This study aimed at determining the efficacy of
rapamycin and rapalogs for reducing the size of TSC-associated solid tumors in patients with Tuberous Sclerosis
Complex (TSC).
Methods: Our data sources included electronic searches of the PubMed. We included into our meta-analysis any type
of non-randomized study that reported the use of rapamycin and rapalogs for reducing the size of TSC-associated solid
tumors in patients with TSC. Data was entered into Cochrane Review Manager Version 5.3 and analyzed.
Results: Four case reports and 4 clinical trials were included. Five patients from the case reports (all with SEGA)
and 91 patients from the clinical trials (41 with SEGA, 63 with kidney angiomyolipoma and 5 with liver
angiomyolipoma) were included into the analysis. Volume and diameter of SEGAs were significantly reduced by
mean difference of 1.23 cc (95 % CI −2.32 to −0.13; p = 0.03) and 7.91 mm (95 % CI −11.82 to −4.01; p < 0.0001),
respectively. Volume and mean of sum of longest diameter of kidney angiomyolipomas were significantly
reduced by mean difference of 39.5 cc (95 % CI −48.85 to −30.15; p <0.00001) and 69.03 mm (95 % CI −158.05 to
12.65; p = 0.008), respectively. In liver angiomyolipomas, however, reduction in tumor size was not evident. Sum
of longest diameter of liver angiomyolipomas in 4 patients were enlarged by 2.7 mm (95 % CI 28.42 to −23.02)
by the end of treatment, though not significant (p = 0.84).
Conclusions: Rapamycin and rapalogs showed efficacy towards reducing the size of SEGA and kidney
angiomyolipoma but not liver angiomyolipomas. This finding is strengthening the conclusion of our Cochrane
systematic review on the randomized trials.
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Background
Tumor development is a hallmark in the pathogenesis
and diagnosis of Tuberous Sclerosis Complex (TSC).
Nine out of 11 major clinical features in TSC diagnosis
constitute the appearance of tumor structures [1]. A sig-
nificant portion of TSC patients showed tumor develop-
ment. Cortical tubers (CT) occur in 80–90 % [2, 3],
subependymal nodules (SEN) in 90 % [4] and subepen-
dymal giant cell astrocytoma (SEGA) in 5–20 % of TSC
patients. CT has been associated with seizures and de-
velopmental delays [5–7], while SEN is normally dor-
mant but may develop into SEGA which potentially
causes ventricular obstruction, visual impairment, focal
neurologic deficits and endocrinopathies [4, 8].
Kidney angiomyolipoma occurs in 75 % of TSC patients
and is a frequent cause of death due to haemorrhage [9].
Another frequent cause of death among TSC patients is
pulmonary lymphangioleiomyomatosis (LAM) which
occur in 40 % premenopausal females with TSC [10, 9].
Cardiac rhabdomyoma is also commonly found in TSC
patients, although generally regress with increasing age
[11]. Tumors may also manifest in the skin in the forms of
angiofibromas and other cutaneous fibromas [11].
Development of hamartomatous tumors in TSC pa-
tients is related to the mTOR (mammalian target of rapa-
mycin) pathway that acts as a central regulator of many
functions, including cell size/growth and proliferation.
mTOR combines with several other cellular components
to form two distinct complexes, termed mTORC1 and
mTORC2 [12], of which only mTORC1 is inhibited by
rapamycin and rapalogs. Nutrient stimulation stimulates
mTORC1 through activation of PI3 kinase (PI3K) and in-
hibition of Hamartin/Tuberin Complex. Upregulation of
mTORC1 activates S6 kinase1 (S6K1) and ribosomal S6
kinase (rS6), and inhibits eukaryotic translation initiation
factor 4E-binding protein 1 (4EBP1) and eukaryotic initi-
ation factor 4E (eIF4E), which results in cell growth and
proliferation. (Reviewed in [13]). Figure 1 illustrates the
mTOR pathway and mTOR inhibition through rapamycin-
FKBP12 complex.
mTOR kinase inhibition was thought to be a useful
approach to systemic therapy for TSC and/or LAM be-
cause rapamycin, an mTOR inhibitor, has been shown to
normalize dysregulated mTOR signaling in cells that
lack normal hamartin or tuberin [14–19].
Rapamycin (otherwise known as sirolimus) is an in-
hibitor of mTOR. In fact, rapamycin sensitivity has been
used as the major criterion to identify mTOR-controlled
events [20]. Rapamycin (C51H79NO13) is a macrolide
compound that was isolated in 1975 from Streptomyces
hygroscopicus found in a soil sample on Easter Island. It
prevents activation of T cells and B cells by inhibiting
their response to interleukin-2 (IL-2). It is an FDA-
approved drug for immunosuppression after organ
transplantation. Rapamycin also possesses both antifun-
gal and antineoplastic properties [21].
The mechanism by which rapamycin inhibits mTOR is
not fully understood but rapamycin associates with
FKBP12 to bind to the FRB (FKBP12–rapamycin-binding)
domain of mTOR. Binding of the rapamycin–FKBP12
complex to mTOR can destabilize the mTORC1 complex
and interfere with the activation of mTOR by phospha-
tidic acid. Several new compounds are available to inhibit
mTOR, either by interfering with complex formation
(FKBP12-dependent or FKBP12-independent) or by dir-
ectly inhibiting the catalytic domain of mTOR [22].
A previous study utilizing cohorts of Tsc2+/−mice and
mouse model of Tsc2-null tumors showed that treatment
with an mTOR kinase inhibitor (CCI-779, a rapamycin
analogue) reduced the severity of TSC-related disease
without significant toxicity [23].
Everolimus, a rapamycin analogue, has been studied in
multiple randomized controlled trials for various indica-
tions with mostly promising efficacy and safety results
such as in de-novo liver transplant patients [24], cardi-
ology patients [25, 26], patients with metastatic renal cell
carcinoma [27, 28], patients with neuroendocrine tumors
(NET) [29, 30] and breast cancer [31].
A high proportion of tumor manifestations increas-
ingly correspond with the morbidity and mortality due
to tumor development in TSC patients. Previous non-
human studies have shown the potential application of
rapamycin and rapalogs for TSC. Our Cochrane System-
atic Review on the randomized studies have shown that













Fig. 1 mTOR pathway and inhibition of mTOR through
Rapamycin-FKBP12 complex
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patients who achieved 50 % reduction in tumor size within
the subjects group that received rapamycin and rapalogs
(Protocol published [32]). However, we have been unable
to measure the rapamycin and rapalogs effect on the abso-
lute tumor size, as this latter outcome was only reported
in non-randomized studies. Here we analyzed rapamycin
and rapalogs effect on the absolute tumor size in patients
with Tuberous Sclerosis Complex.
Methods
There is no published protocol for this systematic re-
view. This systematic review was checked for complete-
ness based on PRISMA 2009 Checklist [33].
Criteria for considering studies for this review
Types of studies
All types of published non-randomized studies (as de-
fined in the Cochrane Handbook version 5.1 [34]) using
English language and encountered online through
PubMed searches were analyzed.
Types of participants
People with known TSC-associated SEGA, kidney angio-
myolipoma and/or liver angiomyolipoma as proven by
the clinical features designated in the 2012 consensus
diagnostic criteria for TSC and/or TSC-causing muta-
tions in either TSC1 or TSC2 gene [1]. Studies and/or
participants without solid tumors or non-TSC-associated
tumors were excluded.
Types of interventions
Any rapamycin or its analogues (rapalogs) designed to
reduce the size of TSC-associated tumors in patients
with Tuberous Sclerosis Complex
Types of outcome measures
We chose tumor volume or diameter as primary out-
come. We also reported adverse effects whenever they
are described as related to the rapamycin and rapalogs
administration.
Search methods for identification of studies
Electronic searches in PubMed used keywords “TSC
AND [SEGA OR kidney angiomyolipoma OR liver
angiomyolipoma] AND [rapamycin OR sirolimus OR ta-
crolimus OR everolimus]”. All published articles and ab-
stracts were searched. The search was limited to reports
on human studies using English language.
Data collection and analysis
Statistical analysis
Available data (mean and standard deviation of each
cohort study and pooled case reports) was entered into
Cochrane Review Manager Version 5.3 [35] for analysis
of treatment effects.
Selection of studies
Studies were selected according to the criteria for con-
sidering studies for this review, as described above.
Please refer to the PRISMA diagram illustrating the
study selection (Fig. 2).
Data extraction
Data was extracted using the specially designed data ac-
quisition form as used in the Cystic Fibrosis and Genetic
Disorders Group of The Cochrane Collaboration. The
following items were extracted : type of study, partici-
pants and trial characteristics (single/multi-center, coun-
tries, eligibility, number of participants in the study,
number of participants included in this review), inter-
vention details (type of rapamycin or rapalogs, adminis-
tering dose, trough level, duration of treatment, median
or range of follow-up), outcomes (tumor volume and/or
diameter) and rapamycin-related adverse effects.
Fig. 2 Study flow diagram (based on The PRISMA Statement [33])
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Risk of bias assessment
The risk of bias of each included study was assessed
using the 8-item Newcastle-Ottawa Scale for observa-
tional studies [36].
Measures of treatment effect
We recorded continuous data such as tumor volumes or
diameter as mean baseline and post treatment values
and standard deviation (SD) for each group. We calcu-
lated a pooled estimate of the treatment effect at the end
of each core length of treatment for each outcome
across studies by determining the mean difference. We
pooled outcome data from case reports into one group.
Assessment of heterogeneity
Test for heterogeneity between studies was done using a
standard Chi2 test and I2 statistic [37]. The Chi2 test is a
statistical test for heterogeneity, whereas I2 assesses the
quantity of inconsistency across studies in the meta-
analysis. We used a cut-off P value of 0.1 to determine
significance. This is because of generally anticipated low
power of the reported trials due to the disease being
rare. We used the following I2 ranges to interpret het-
erogeneity: 0 to 40 %: might not be important, 30 to
60 %: may represent moderate heterogeneity, 50 to 90 %:
may represent substantial heterogeneity and 75 to
100 %: considerable heterogeneity.
Results and discussion
Characteristic of studies
Results of the search
Fourteen studies were identified from the searches (Fig. 2).
Screening of abstracts excluded two studies [38, 39] be-
cause the studies measured the organ’s volume/size in-
stead of the tumor’s. These are case reports with one
patient each. Further full-text assessments excluded four
studies with unit analysis/measurement or diagnosis issues
[40–43]. One was a prospective cohort study involving 25
patients with angiomyolipoma or lymphangioleiomyoma-
tosis where the TSC-diagnosed patients were mixed up
with non TSC-diagnosed patients [40] and the rest were
case reports with 1 patient each [41–43]. This review fi-
nally included eight studies consisting of four case reports
[44–47] and four prospective cohort studies [48–51].
Included studies (Table 1)
Characteristics of case reports
Franz et al. [44] reported four patients with SEGA
altogether. However, only three patients (1 male 2 females,
aged 14.5 – 21 years old) were reported with mutations in
TSC2 gene. We excluded one patient of this report due to
unclear TSC diagnostic data. The patients were treated
with rapamycin 2 – 6 mg/day to achieve trough level of
7.7 – 10.9 ng/ml for 2.5 – 20 months.
Wienecke et al. [47] reported 1 patient (male, aged
19 years old) with kidney angiomyolipoma, in whom a
mutation of TSC2 was identified. The patient was treated
with rapamycin 1 mg every other day – 2 mg/day to reach
trough level of 4 – 5 ng/ml for 7 months. Birca et al. [45]
reported 1 patient (female, 8 years old) with SEGA. The
patient showed clinical features of TSC as well as continu-
ous deletion of TSC2/PKD1 region. Treatment with rapa-
mycin was 1 – 2 mg/day to reach trough level of 3.3 –
4.5 ng/ml. Treatment duration was not mentioned, but
last follow-up was after 5 months of treatment. Lam et al.
[46] reported 3 patients with TSC-associated SEGA and
kidney angiomyolipoma. However, we could only analyzed
1 patient (male, 9 years old) since the remaining 2 patients
were reported as percentage decrease in tumor size and
Table 1 Characteristics of included studies
Study type Case report Cohort prospective
Studies Franz 2006 Wienecke 2006 Birca 2010 Lam 2010 Krueger 2010 Dabora 2011 Lopez 2011 Davies 2011
na 3 1 1 1 28 36 17 10
Sex M 1 1 1 17 10 8 NS
F 2 1 11 26 9
Age range (years) 14.5 – 21 19 8 9 3 – 34 19 – 60 >10 NS
Genotype TSC1 4
TSC2 3 1 1 1 10 14
Unknown 14 22 17 10
Rapamycin Dose (mg/day) 2 – 7 0.5 1 5 – 7 3b 2 – 6 1 0.5c
Trough (ng/ml) 7.7 – 10.9 4 – 5 3.3 – 4.5 10 – 15 5 – 15 3 – 15 4 – 8d 3 – 6
NS Not specified
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not the absolute value of tumor volume or diameter. The
patient was treated with rapamycin 5 – 7 mg/day (in com-
bination with carbamazepine that is known to induce
rapamycin metabolism) to reach trough level of 10 –
15 ng/ml for a year. However, the follow-up reported was
only that of 3 months.
Characteristics of prospective cohort studies
Krueger et al. [51] was described as a prospective, open-
label, phase I-II trial. It was carried out in a single center
at the Cincinnati Children’s Hospital Medical Center (US).
The study reported 28 patients (17 males and 11 females;
aged 3 – 34 years old) with definitive diagnosis of TSC
and SEGA. The patients were treated with Everolimus or-
ally at a starting daily dose of 3.0 mg per square meter of
body-surface area and were subsequently adjusted to at-
tain a whole-blood trough concentration of 5 – 15 ng/ml.
The participants were essentially treated for 6 months
with a median length of follow-up of three months.
Dabora et al. [49] was described as an open label, single
arm, multicenter study with a Simon two-stage design
[52]. It was carried out in six clinical centers at the United
States (Boston, Cincinnati, Loma Linda, Hartford, New
York and Dallas). The study reported 36 patients (10
males and 26 females; aged 19 – 60 years old) with defini-
tive diagnosis of TSC, all with kidney angiomyolipoma, 13
with SEGA and 4 with liver angiomyolipoma. The patients
were treated with Sirolimus orally at a loading dose of
6 mg followed by 2 mg/day to achieve trough level of 3 –
9 ng/ml during the first 16 weeks. After 16 weeks, the
dose was increased to achieve a trough level of 9 – 15 ng/
ml. The treatment lasted for 12 months with a median
length of follow-up of 4 months.
Cabrera-Lopez et al. [48] was described as a phase IV
non-blinded, non-controlled clinical trial. It was carried
out at a single center in Spain. The study reported 17 pa-
tients (8 males and 9 females older than 10 years of age)
with TSC diagnosis showing kidney angiomyolipoma. The
patients were treated with rapamycin with initial dose of
1 mg/day. The dosage was increased 1 mg/day every for
two weeks until it reached stable trough concentration of
4 – 8 ng/dl. The treatment lasted for 12 months with a
median length of follow-up of 6 months.
Davies et al. [50] was described as phase II non-
randomized, open-label multicenter trial. It was carried
out in 4 hospitals of the United Kingdom and Switzerland.
The study reported 16 patients, out of which only 10
patients were with definitive diagnosis of TSC and
showing kidney angiomyolipoma. The patients were
treated orally with sirolimus at initial dosage of 0.5 mg/
square meter of body surface. The dosage was adjusted
to achieve trough concentration of 3 – 6 ng/ml. The
treatment lasted for 24 months with a median length of
follow-up of 5 months.
Risk of bias assessment
The results of the risk of bias assessments for individual
studies are reported in Table 2. Overall, each study
showed high to low risk of bias.
Effects of interventions on tumor size
Five patients from the case reports (all with SEGA) and
91 patients from the clinical trials (41 with SEGA, 63
with kidney angiomyolipoma and 5 with liver angiomyo-
lipoma) were included into the analysis. An additional 3
patients from the case reports (1 with kidney angiomyo-
lipoma [47] and 2 with SEGA [46]) were described, al-
beit not systematically analyzed.
SubEpendymal Giant cell Astrocytoma (SEGA) (Table 3)
In total, there are 5 studies that looked at the effect of
rapamycin or rapalogs on SEGA, in which 3 are case re-
ports [44–46] and 2 are prospective cohort [49, 51]. Two
studies used tumor volume (cc) [51, 44] and 3 studies used
tumor diameter (mm) [49, 45, 46] as their unit of analysis.
The case reports [44–46] comprised of 5 patients with
SEGA. From Franz et al. [44] we included 3 patients using
tumor volume (cc) as unit of analysis. Lengths of treat-
ment are variable, ranging from 2.5 – 20 months. Reduc-
tion in the tumor volume was noted in all patients, with a
mean difference of −1.7 cc (95 % CI −4.6 to 1.2; p = 0.3).
Birca et al. [45] reported one patient on which we took
the longest tumor diameter (mm) as unit of analysis.
Length of treatment was 5 months. There are two SEGAs
found in this patient, from which we took the average for
analysis. At 3-month follow-up tumor 1 was reduced from
38.7 mm to 24.3 mm while tumor 2 was also reduced
from 31.3 mm to 21.8 mm. No further reduction in tumor
size was noted at 5-month follow-up. From Lam et al. [46]
we analyzed only one out of 3 patients using tumor lon-
gest diameter (mm) as unit of analysis. Length of treat-
ment was 9 months. At 3-month follow-up the tumor was
reduced from 35 mm – 26 mm. No further reduction in
tumor size was noted at 6- and 9-month follow-ups. Re-
duction in the tumor diameter was noted in these 2 pa-
tients, with a mean difference of −12.00 mm (95 % CI
−17.70 to −6.30; p = 0.05). The other 2 patients showed
significant reduction in tumor size of 50–60 % of the pre-
treatment size [46].
Dabora et al. [49] reported 13 patients with measur-
able SEGA ranging in diameter from 9–30 mm. How-
ever, follow-up data was only available from 11 patients
after 12 months of Sirolimus treatment. Tumor regres-
sion was observed in 7 cases and SEGA diameter was
stable in the other 4 cases. Our analysis showed that the
SEGA in these 11 patients were reduced by mean differ-
ence of −4.3 mm (95 % CI −9.66 to 1.06; p = 0.1).
Krueger et al. [51] reported 28 patients with SEGA
whereby one patient was withdrawn at 4.5 months. This
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Krueger 2010 Truly representative* No non-exposed cohort Secure record* Yes* No Record
linkage*
Yes* Complete* 6
Dabora 2011 Truly representative* No non-exposed cohort Secure record* Yes* No Record
linkage*
Yes* 8 out of 36 lost follow-up
(22 %)*
6
Davies 2011 Truly representative* No non-exposed cohort Secure record* Yes* No Record
linkage*
Yes* 4 out of 16 lost follow-up
(25 %)*
6
Lopez 2011 Truly representative* No non-exposed cohort Secure record* Yes* No Record
linkage*
Yes* 1 out of 17 lost follow-up (5 %)* 6
aLength of follow-up of at least 6 months is considered sufficient














study reported two versions of assessment at 6-month of
follow-up; that of the local investigator’s and that of the
independent central review. We include only the latter
in our analysis. Local investigator’s assessment examined
the tumor volume (cc) at 3, 6, 12, 18 and 24 months.
We noted fluctuation in the mean of tumor volume re-
duction of 3 months (0.88 cc), 6 months (1.04 cc),
12 months (0.99 cc), 18 months (1.11 cc) and 24 months
(0.87 cc) as compared to baseline. Our analysis showed
that SEGA in 27 patients after 6 months of follow-up were
reduced by mean difference of −1.01 (95 % CI −2.33 to
0.03; p = 0.06).
Overall, volume of SEGAs in 30 patients was significantly
reduced (p = 0.03) after 3–12 months therapy, by mean dif-
ference of −1.23 cc (95 % CI −2.32 to −0.13). Similar pat-
tern was also noted in the diameter of SEGAs in 13
patients (p < 0.0001) after 5–12 months treatment, by mean
difference of −7.91 mm (95 % CI −11.82 to −4.01).
Kidney angiomyolipoma (Table 4)
There are 4 studies that looked at the effect of rapamy-
cin on kidney angiomyolipoma. One is a case report [47]
and three are cohort prospective [48–50]. Cabrera Lopez
et al. [48] and Wienecke et al. [47] used tumor volume
(cc), while Dabora et al. [49] and Davies et al. [50] used
tumor diameter (mm) as their unit of analysis.
Wienecke et al. [47] reported 1 patient with baseline
tumor volume of 134 cc before administration of Rapa-
mycin. Five months following Rapamycin therapy, MRI
showed the tumor shrunk to 39 cc. The tumor volume
was further reduced to 23 cc at 7 months following
treatment. At 7 months, Rapamycin treatment was ter-
minated. As a result, 15 months after the initial treat-
ment, the tumor re-grew to 116 cc, following which
rapamycin was re-instutited. A rapid decrease in tumor
volume (to 45 cc) was noted after 3 months.
Cabrera Lopez et al. [48] reported 17 TSC patients
with kidney angiomyolipoma, out of whom one had to
be withdrawn from the study after 11 months due to re-
activation of an erythema nodosum which was already
present at the start of the trial, and another patient was
removed from the study after 13 months of treatment
due to the appearance of nephrotic proteinuria which
disappeared after treatment suspension. Length of treat-
ment was 24 months. Tumor volume was examined at
6-month and 12-month following the treatment. At 6-
month follow-up the tumor size was significantly de-
creased by mean difference −34.00 cc (95 % CI 24.62 to
−43.38; p = 0.0000). The tumor size further shrunk at
12-month follow up by mean difference of −39.50 cc
(95 % CI −48.85 to −30.15; p = <0.00001).
Dabora et al. [49] reported 36 TSC patients with kid-
ney angiomyolipoma, out of whom 8 were withdrawn
from the study. These included 4 who were unable to
come for study appointments, and 4 who were taken off
study because of a serious adverse event that was judged
unrelated to drug therapy (1 hospitalized with compli-
cated infectious mononucleosis, 1 diagnosed with a pan-
creatic neuroendocrine tumor, 1 hospitalized with a
kidney angiomyolipoma hemorrhage, 1 hospitalized with
Table 4 Outcome on kidney angiomyolipoma
Studies Volume (cc) Sum of longest diameter (mm)
Baseline n After treatment n Mean diff (95 % CI) Baseline n After treatment n Mean diff (95 % CI)
Cabrera Lopez 2011 62.6 ± 18.3 17 23.1 ± 7.0 16 −39.5 (−30.15,–48.85)
Dabora 2011 212 ± 146 36 145 ± 113 28 −67 (−3.55,–130.5)
Davies 2011 135.5 ± 135.6 10 62.8 ± 20.1 7 −69.80 (15.39,–154.99)
Overall Effect −39.5 (−48.85, −30.15) −69.03 (−158.05, 12.65)
p = <0.00001 p = 0.008
Heterogeneity Not applicable Chi2 = 0.01; I2 = 0 %
Table 3 Outcome on Subependymal Giant Cell Astrocytoma (SEGA)
Studies Volume (cc) Diameter (mm)
Baseline n After treatment n Mean diff (95 % CI) Baseline n After treatment n Mean diff (95 % CI)
Case Reports 2.9 ± 2.4 3 1.2 ± 0.9 3 −1.7 (−4.6, 1.2) 35 ± 3.7 2 23 ± 1.8 2 −12.00 (−17.70, −6.30)
Kruger 2010 2.45 ± 2.81 28 1.3 ± 1.48 27 −1.01 (−2.33, 0.03)
Dabora 2011 16.7 ± 6.4 13 12.4 ± 6.9 11 −4.3 (−9.66, 1.06)
Overall Effect −1.23 (−2.32, −0.13) −7.91 (−11.82, −4.01)
p = 0.03 p < 0.0001
Heterogeneity Chi2 = 0.12; I2 = 0 % Chi2 = 3.72; I2 = 73 %
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a neurologic event). Core length of treatment was
12 months. Follow-ups were done at 4, 8 and 12 months.
Sum of the longest diameter (SLD) of the tumor (mm) was
used as unit of analysis. At 4-month follow up (n = 33), the
tumor SLD decreased but not significantly (p = 0.28) by
mean difference of −36.00 mm (95 % CI 28.67 to −100.67).
At 8-month follow-up (n = 29), the tumor SLD further de-
creased (p = 0.05) by mean difference of −62.00 mm (95 %
CI 0.04 to −124.04). At 12-month follow-up (n = 28), the
tumor SLD further decreased (p = 0.05) by mean difference
of −67.00 mm (95 % CI −3.55 to −130.45).
Davies et al. [50] reported 10 TSC patients with kidney
angiomyolipoma, out of whom 3 were withdrawn.
Length of treatment was 24 months. SLD of the tu-
mors was taken as unit of analysis. Follow-ups were
done at 2,6,12 and 24 months. At 2 months (n = 9),
the tumor SLD was decreased (p = 0.9) by mean differ-
ence of −8.00 mm (95 % CI 118.15 to −134.15). At
6 months (n = 10), the tumor SLD was further de-
creased (p = 0.79) by mean difference of −16.3 mm
(95 % CI 103.13 to −135.73). At 12 months (n = 8), the
tumor SLD was decreased (p = 0.11) by mean differ-
ence of −69.8 mm (95 % CI 15.39 to −154.99). Again,
at 24 months (n = 7), the tumor was decreased further
(p = 0.2) by mean difference of −69.8 mm (95 % CI
15.39 to −154.99). It is of note that at follow-ups of 12
and 24 months, 3 patients with 18 tumor lesions were
withdrawn.
Overall, volume of kidney angiomyolipoma in 16 pa-
tients was significantly reduced (p <0.00001) by mean dif-
ference of −39.5 cc (95 % CI −48.85 to −30.15) after
12 months rapamycin therapy. This reduction was also
noted in the mean of SLD of the kidney angiomyolipomas
in 35 patients (p = 0.008) by −69.03 mm (95 % CI −158.05
to 12.65). In total, 11 patients with kidney angiomyolipo-
mas were withdrawn before 12 months of therapy.
Liver angiomyolipoma
There is only one study that looked into the effect of
rapamycin on liver angiomyolipoma, which is a pro-
spective cohort [49]. This study used the tumor’s SLD as
the analysis unit. There are 5 TSC patients with measur-
able liver angiomyolipoma, out of which 1 was with-
drawn before 12 months of treatment. Core length of
treatment was 12 months. Follow-ups were done at 4, 8
and 12 months. At 4-month follow-up (n = 4), the tumor
SLD was decreased (p = 0.05) by mean difference of
−12.80 mm (95 % CI −0.1 to −25.5). At 8-month follow-
up (n = 4), the tumor SLD was still smaller as compared to
that of baseline (p = 0.08) by mean difference of −12.5 mm
(95 % CI 1.33 to −26.33) but this slightly re-grew as
compared to that at 4-month follow-up. At 12-month
follow-up, the tumor SLD was slightly larger (p = 0.84) as
compared to that of baseline by mean difference of 2.7 mm
(95 % CI 28.42 to −23.02). Reduction of tumor size in liver
angiomyolipoma was not evident.
Adverse effects
Summary of adverse effects found in 99 patients from the
included studies was described in Table 5. The most
Table 5 Adverse effects in 99 patients
Adverse effect Percentage of patients
Oral ulcer 54.5
Hypertriglyceridemia 28.3













Urinary Tract Infection 7.1
Headache 6.1
Lymphopenia 6.1





Incerased ALT, SGPT 4
Gastric Infection 3
Cough 3
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frequent adverse effects were oral ulcer followed by
hypertriglyceridemia and upper respiratory tract infection.
We identified, in this systematic review, 8 studies that
fulfill our criteria for study inclusion involving a total of
99 trial participants. Six patients from the case reports
(5 with SEGA, 1 with kidney angiomyolipoma) and 91
patients from the prospective cohorts (41 with SEGA, 63
with kidney angiomyolipoma and 5 with liver angiomyo-
lipoma) were included into the analysis. Two other pa-
tients were described from a case report, albeit not
analyzed.
On the quality of the included studies, we admit that
we only included in this analysis non-randomized stud-
ies which by itself were a limitation. However, although
the case reports may be of moderate to high risk of bias,
the prospective cohort studies that we included may be
categorized into moderate to low risk of bias, to the ex-
tent possible as non-randomized studies. There is a not-
able variability in the duration of follow-up, which might
affect treatment outcome.
Thirty-one patients with SEGA were analyzed for their
tumor volume (cc), while 15 patients for their tumor
diameter. Analyses using both units showed a significant
reduction in the size of SEGAs following the treatment.
The volume was significantly reduced after 3 – 12 months
of rapamycin administration by 1.23 cc and 2.45 stretch of
reduction interval. The diameter, on the other hand,
showed stretch of reduction interval of 7.81 and a mean
reduction of 7.91 mm after 5 – 12 months therapy.
Forty-six patients with kidney angiomyolipomas were
analyzed of their tumor’s sum of longest diameter (mm),
while 17 patients of their tumor volume (cc). Both ana-
lyses showed significant reduction in the size of kidney
angiomyolipoma following the treatment. The sum of
longest diameters was significantly reduced by 69.03 mm
and a stretch of reduction interval of 170.7. The volume
was also significantly reduced by 39.50 cc with a stretch
of reduction interval of 18.7. However, there are 12 pa-
tients withdrawn from the study before completion of
12 months therapy.
These have shown that rapamycin and rapalogs signifi-
cantly reduce the tumor size in Tuberous Sclerosis pa-
tients with SEGA and kidney angiomyolipomas.
However, the same reduction in tumor size was not evi-
dent in liver angiomyolipomas which involve only a lim-
ited set of patients.
Rapamycin has also been tried on other manifestations
of Tuberous Sclerosis Complex with mostly promising
results, albeit variable degree of evidences. Reports de-
scribed improvement in facial angiofibroma [53–56],
epilepsy [57, 58], cardiac rhabdomyoma [59], lymphan-
gioleiomyomatosis [40, 50], fibromatosis and renal cell
carcinoma [60] but not the optic nerve tumor [42]
among patients with Tuberous Sclerosis Complex.
Our Cochrane systematic review (Protocol published
[32]) on the same treatment effect which included only
randomized studies [61–63] showed that there is a sig-
nificant increase in the proportion of patients who
achieved 50 % reduction in tumor size within the partici-
pants group that received rapamycin and rapalogs. This
used dichotomous data for its analyses. The current art-
icle meta-analyzed non-randomized studies for the effect
of rapamycin and rapalogs on tumor size and used con-
tinuous data for its analyses (actual tumor volume and
diameter).
Adverse effects of the rapamycin treatment should be
highlighted given that slightly more than half of the pa-
tients showed at least one of the listed adverse effects
(Table 5). However, only very few were reported to de-
velop serious conditions [49, 51].
Conclusion
As a conclusion, we have shown that rapamycin and rapa-
logs reduce the size of SEGA and kidney angiomyolipoma
in patients with Tuberous Sclerosis Complex. This result
strengthens our Cochrane systematic review on random-
ized studies. However, it is of note that we are unable to
rule out the possibility of publication bias where authors
only report positive outcomes and there may be many in-
stances where no response was unreported.
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